UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Organoid Acquired Resistance
Organoid Acquired Resistance is a funding opportunity from UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, up to 212804, closing August 31, 2027.
Aug 31, 2027
(396d left)Overview
PROJECT SUMMARY The overall goal of Project 3 of this U54 application is the organoid-based definition of mechanisms of acquired resistance (AR) to targeted therapy in non-small cell lung cancer (NSCLC). The treatment of NSCLC employs numerous therapies directed against the EGFR, ALK, KRAS G12C, ROS1 and PD-1/PD-L1…